国内首个FDA制剂文号ANDA078644--奈韦拉平片[综合ZT]
华海药业公告:
3 F3 a0 B& D' l6 m2 ?1 Thttp://www.sse.com.cn/cs/zhs/scf ... 0521_20070713_1.pdf
9 `' C9 a+ u" XFDA网站信息:
/ ]3 x! @4 \" Jhttp://www.accessdata.fda.gov/sc ... =Search.DrugDetails
% h4 [8 _0 C3 v. VFDA给华海的Letter:
' k) B3 o. H7 x8 k2 Q. {http://www.fda.gov/cder/foi/appletter/2007/078644s000TAltr.pdf% }) f( l8 r* u- F5 `, I
President's Emergency Plan for AIDS Relief中华海的NEVIRAPINE: & Z2 t! _# |9 v: k% o
http://www.fda.gov/oia/pepfar.htm
1 v+ V1 W: `, O4 P6 g7 P浙江华海药业股份有限公司网址:' B8 ^6 I0 D+ D8 y- O
http://www.huahaipharm.com/web/index.asp
% R- a- H) k- j* h' C' t. I1 W G/ C, N" s& t% M8 D
关于“Marketing Status”中“Tentative Approval”的注释:
) |5 w, `5 O+ j( q* |# V& c dTentative Approval: 0 X% b% d5 b' J# l( ?, _. C
If a generic drug product is ready for approval before the expiration of any patents or exclusivities accorded to the reference listed drug product, FDA issues a tentative approval letter to the applicant. The tentative approval letter details the circumstances associated with the tentative approval. FDA delays final approval of the generic drug product until all patent or exclusivity issues have been resolved. A tentative approval does not allow the applicant to market the generic drug product.
' g( C/ r' {% t* `: }9 l( v也就是本品的状态为Tentatively Approved(FDA的暂时批准)意味着:由于专利权和/或独占权(exclusivity)的原因无法在美国上市,但它符合用于在美国上市的FDA质量、安全和有效性标准。但根据AIDS救援紧急计划(President's Emergency Plan for AIDS Relief)这些临时批准的产品可能被采购。 |